Compare AMPL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | NRIX |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | AMPL | NRIX |
|---|---|---|
| Price | $11.62 | $19.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $14.91 | ★ $27.46 |
| AVG Volume (30 Days) | 1.1M | ★ 1.8M |
| Earning Date | 02-18-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $329,919,000.00 | $83,687,000.00 |
| Revenue This Year | $16.61 | $59.40 |
| Revenue Next Year | $13.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.78 | ★ 48.32 |
| 52 Week Low | $7.55 | $8.18 |
| 52 Week High | $14.88 | $22.50 |
| Indicator | AMPL | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 60.28 |
| Support Level | $11.35 | $18.78 |
| Resistance Level | $12.05 | $19.54 |
| Average True Range (ATR) | 0.42 | 0.84 |
| MACD | 0.00 | -0.21 |
| Stochastic Oscillator | 68.61 | 68.92 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.